Abstract: NCAPG2, a component of condensin complex II, protein and novel peptides derived from the protein are provided. The peptide may include a fragment of the NCAPG2 protein. The peptide may be a peptide including a fragment of NCAPG2 protein having the amino acid sequence of SEQ ID NO: 7, wherein the fragment includes the amino acid residue number 805 or 1010 of SEQ ID NO: 7, a peptide having the sequence of SEQ ID NO: 8, or a peptide having the sequence of SEQ ID NO: 11. The protein or peptides can be used for preparing and screening pharmaceutical compositions for treating diseases or disorders associated with abnormal cell division including cancer.

Abstract: The disclosure relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection.

Abstract: Isolated protein complexes are provided comprising keratinocyte growth factor and vitronectin, or at least domains thereof that enable binding to and activation of both a keratinocyte growth factor receptor and an integrin receptor for vitronectin. These protein complexes include synthetic proteins where the keratinocyte growth factor and vitronectin sequences are joined by a linker sequence. In particular forms, vitronectin sequences do not include a C-terminal heparin binding domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement, skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer.

Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.

Abstract: The present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD 154, which is important in inflammation. The present invention also relate to the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present invention also relates to the use of such short peptides to prevent or reverse autoimmune disease, and particular, diabetes, in individuals suffering from such disease. It also relates to methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells.

Abstract: The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.

Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.

Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Abstract: An antibody or antigen-binding fragment thereof that specifically binds to and inhibits VEGF-C and uses thereof in a method of inhibiting angiogenesis and a method of preventing, treating, and/or diagnosing a disease associated with activation and/or overexpression of VEGF-C, using the antibody, and a method of detecting the presence of VEGF-C in a sample.

Abstract: The invention relates to minimizing the progression of cancer in a companion animal using P2X7 immunotherapy.

Abstract: Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer.

Abstract: Problem to be Solved The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenesis effect in in-vivo models.

Abstract: This invention relates to compositions comprising anti-CD83 agonist antibodies and methods of treating autoimmune disorders (such as inflammatory bowel disease) with anti-CD83 agonist antibodies, as well as articles of manufacture comprising anti-CD83 agonist antibodies.

Abstract: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.

Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.

Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Abstract: The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Abstract: The invention provides a method for the prophylaxis, improvement, or treatment of inflammatory bowel disease, multiple sclerosis, and psoriasis by administering to a subject an effective amount of an isolated anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of amino acid numbers 80 to 175 of SEQ ID NO:22.

Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.

Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.

Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.

Abstract: Provided are bispecific antibodies comprised of a single-chain unit having specificity to an immune cell and a monovalent unit having specificity to a tumor cell or a microorganism. The single-chain unit includes a single-chain variable fragment (scFv) fused to an Fc fragment and the monovalent unit includes a light chain and heavy chain pair. Also provided are methods of preparing bispecific antibodies and pharmaceutical and diagnostic uses of these antibodies.

Abstract: The present invention relates to a soluble hydrophobic-core carrier composition comprising (i) a linear polymeric backbone; (ii) a plurality of hydrophilic polymeric protective chains covalently linked and pendant to the polymeric backbone and (iii) at least one hydrophobic moiety covalently linked and pendant to the polymeric backbone. In certain embodiments, the weight ratio of hydrophilic protective chains to hydrophobic moieties in the carrier is at least 15:1. In other embodiments, at least 90% of the residues of the polymeric backbone are coupled to a hydrophilic polymeric protective chain or a hydrophobic moiety. In other embodiments, the composition further comprises (iv) a hydrophobic load molecule dissociably linked to the hydrophobic moiety of the carrier.

Abstract: Functionalized alternan, comprising carboxy groups as functional groups, wherein the alternan can be described by the following formula (I) Alternan (I) wherein R1 is a hydrocarbon group with 1 to about 100 carbon atoms, optionally featuring one or more heteroatoms, wherein the oxygen between “Alternan” and R1 in Formula (I) is an oxygen of an ether group, as well as the procedures for producing such a functionalized alternan in a aqueous medium or using an alcohol or an alcohol-water mixture as a reaction medium, and the use of this functionalized alternan.

Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.

Abstract: Cyclic carbonate azide having a structure according to the following formula (A) wherein R1-R5 are independently selected from the group consisting of hydrogen, C6-20 aryl, C7-36 aralkyl, and C1-30 alkyl groups; said aryl, aralkyl, and alkyl groups my optionally be substituted with heteroatoms, X is a hydrocarbon moiety having at least one carbon atom, T has the structure —N(R6)— or —O—, R6 is selected from the group consisting of hydrogen and C1-20 alkyl groups, optionally substituted with heteroatoms, k is 0, 1, or 2, m is 0 or 1, n is 0 or 1, p is 1 or 2, Z is an aliphatic or aromatic hydrocarbon moiety having at least one carbon atom, optionally substituted with heteroatoms, and Y is either (B) or C) or (D).

Abstract: The present invention provides an easy-to-handle dispersion stabilizer for suspension polymerization that meets the following requirements: even if the amount of the dispersion stabilizer for suspension polymerization used for suspension polymerization of a vinyl compound is small, the resulting vinyl resin has high plasticizer absorptivity and is easy to work with; it is easy to remove residual monomer components from the resulting vinyl resin; and the resulting vinyl resin contains fewer coarse particles. The present invention relates to a dispersion stabilizer for suspension polymerization in the form of an aqueous liquid. This dispersion stabilizer contains, at a concentration of 20 mass % or more and 50 mass % or less, a PVA having a degree of saponification of 35 mol % or more and 65 mol % or less, a viscosity average degree of polymerization of 100 or more and 480 or less, a terminal aliphatic hydrocarbon group having 6 to 12 carbon atoms, and a block character of residual ester groups of 0.5 or more.

Abstract: The invention relates to a method for preparation of ruthenium-based carbene catalysts with a chelating alkylidene ligand (“Hoveyda-type catalysts”) by reacting a penta coordinated ruthenium (II)-alkylidene complex of the type (L) (Py)X1X2Ru(alkylidene) with a suitable olefin derivative in a cross metathesis reaction. The method delivers high yields and is conducted preferably in aromatic hydrocarbon solvents. The use of phosphine-containing Ru carbene complexes as starting materials can be avoided. Catalyst products with high purity, particularly with low Cu content, can be obtained.

Abstract: A process for producing an isobutene copolymer derivative by: (I) free-radically copolymerizing (a) 10-90 mol % of a monoethylenically unsaturated C4- to C12-dicarboxylic acid, anhydride, or ester, (b) 10-90 mol % of a high-reactivity isobutene polymer having Mn=110-250000 and obtained by polymerizing isobutene in the presence of an iron-halide-, aluminum trihalide-, or alkylaluminum halide-donor complex, each donor being an ether or carboxylic ester function, or in the presence of a Lewis acid complex containing an organic sulfonic acid, and (c) 0-50 mol % of a monoethylenically unsaturated compound copolymerizable with (a) and (b), to obtain an intermediate isobutene copolymer; and (II) reacting the carboxylic acid functions in the intermediate with at least one of ammonia, an amine, and an alcohol, to form a moiety containing at least one of a hydroxyl, carboxylic ester, amino, quaternized amino, amido, and imido group.

Abstract: A robust mesoporous metal-organic framework comprising a hafnium-based metal-organic framework and a single-site zirconium-benzyl species is provided. The hafnium, zirconium-benzyl metal-organic framework is useful as a catalyst for the polymerization of an alkene.

Abstract: The present invention relates to solid catalyst components comprising a reaction product of a titanium compound, a magnesium compound, an alcohol, an aluminum alkoxide, a siloxane mixture, and a maleate derivative; and catalyst systems comprising the solid catalyst components and organoaluminum compounds. The present invention also relates to methods of making the solid catalyst components and the catalyst systems, and methods of polymerizing or copolymerizing ethylene using the catalyst systems.

Abstract: Process for the preparation of (co) polymers of conjugated dienes which comprises polymerizing at least one conjugated diene in the presence of a catalytic system comprising at least one oxo-nitrogenated complex of cobalt having general formula (I), wherein: —R1 and R2, equal to or different from each other, represent a hydrogen atom; or they are selected from linear or branched C1-C20, preferably C1-C15, alkyl groups, optionally halogenated; cycloalkyl groups optionally substituted; aryl groups optionally substituted; —Y represents an oxygen atom; or a group —N—R3 wherein R3 represents a hydrogen atom, or it is selected from linear or branched C1-C20 preferably C1-C15, alkyl groups, optionally halogenated, cycloalkyl groups optionally substituted-; aryl groups optionally substituted; or, when Y represents a group —N—R3, R2 and R3 can be optionally bound to each other to form, together with the other atoms to which they are bound, a cycle containing from 3 to 6 carbon atoms, saturated, unsaturated, or aromati

Abstract: The present invention provides an optically active poly(diphenylacetylene) compound represented by the following formula (I): [wherein each symbol is as described in the DESCRIPTION], and a production method thereof, an optical isomer separating agent containing the poly(diphenylacetylene) compound, and a packing material for a chiral column, containing the optical isomer separating agent coated on a carrier. According to the present invention, a practical optical isomer separation agent having a high optical resolution ability for a wide variety of racemic compounds and an optical isomer separation method can be provided.

Abstract: A resist composition has a resin (A1) including a structural unit having an acid-labile group, a resin (A2) including a structural unit having a group represented by formula (Ia), and an acid generator. wherein R1 in each occurrence independently represents a fluorine atom or a C1 to C6 fluorinated alkyl group, ring W represents a C5 to C18 alicyclic hydrocarbon group, n represents an integer of 1 to 6, and * represents a binding site.

Abstract: The present invention relates to a photocurable composition, to a barrier layer including same, and to an encapsulated device including same, wherein the composition comprises a photocurable monomer(A) and a silicon containing monomer(B), wherein the silicon containing monomers(B) has a structure according to Formula 1.

Abstract: The present invention relates to polynorbornene (PNB) composition embodiments that are useful for forming microelectronic and/or optoelectronic devices and assemblies thereof, and more specifically to compositions encompassing PNBs having norbornene-type repeating units that are polyether functionalized and an additive package containing a phenolic antioxidant and a diaryl amine synergist, and the microelectronic and/or optoelectronic devices made therefrom are resistant to thermo-oxidative chain degradation of said polyether functionalization.

Abstract: The present invention relates to a method to control a liquid feed stream carried out by measuring at least one spectrum of the liquid feed stream comprising an initiator or catalyst, determining its activity using a predictive model on the basis of said spectrum and adjusting the feed streams and/or the preparation conditions of the feed stream comprising the initiators or catalysts in order to attain or maintain a desired level of total activity.

Abstract: According to this invention, a process for producing fluorine containing polymer to obtain composite polymer electrolyte composition having excellent ion transport number, that is, ion transfer coefficient, for example, excellent transport number of lithium ion, is provided. A process for producing fluorine containing polymer comprising graft-polymerizing a molten salt monomer having a polymerizable functional group and a quaternary ammonium salt structure having a quaternary ammonium cation and anion, with a polymer having the following unit; —(CR1R2—CFX)— X means halogen atom except fluorine atom, R1 and R2 mean hydrogen or fluorine atom, each is same or different atom.

Abstract: Block polymers are formed by ring opening polymerization (ROP) of a cyclic carbonate monomer using a polymeric initiator for the ROP that comprises repeating functionalized ethylene units. The block polymers are free of, or substantially free of, any polymer having a chemical structure that does not comprise the polymer backbone of the polymeric initiator. The block polymers are capable of directed self-assembly.

Abstract: A novel copolymer having excellent pigment dispersion performance, and more particularly, a novel copolymer usable as a pigment dispersing agent that can attain high luminance and high contrast of a green picture element in a color filter. The novel copolymer contains: a block chain (A) including a repeating unit having a tertiary amino group; and a block chain (B) including a repeating unit represented by the following formula (I) (wherein R1 represents a hydrogen atom or a C1-C3 alkyl group, R2 and R3 each independently represent a hydrogen atom or a C1-C6 alkyl group, Q represents an oxygen-containing saturated hetero ring group optionally having an alkyl group as a substituent or a C2-C20 alkenyl group, and n represents an integer of 0 to 6), and has an amine value of 80 mgKOH/g or more and 250 mgKOH/g or less.

Abstract: A copolymer includes (i) a plurality of ethylenic moieties A having a structure according to the following formula: wherein R2 and R3 independently represent hydrogen, a halogen, or an optionally substituted linear, branched, or cyclic alk(en)yl group, or an optionally substituted aromatic or heteroaromatic, and (ii) a plurality of acetal moieties B having a structure according to the following formula: wherein L represents a divalent linking group; x=0 or 1; and R1 represents an optionally substituted aromatic or heteroaromatic group including at least one hydroxyl group. Use of these polymers in the coating of lithographic printing plates provides a good abrasion resistance while the balance between the ink acceptance, arising from the ethylenic moieties, and the solubility in an alkaline developer, arising form the acetal moieties, can be controlled efficiently.

Abstract: There is provided an aromatic hydrocarbon formaldehyde resin obtained by reacting an aromatic hydrocarbon compound (A) represented by the following formula (1) with formaldehyde (B) in the presence of an acidic catalyst. wherein R represents an organic group having 1 to 10 carbon atoms; m and n represent integers satisfying 1?m+n?10, m?0 and n?1.

Abstract: The present invention relates to a process for producing a thermoformable rigid polyurethane-polyamide foam having a closed-cell content of less than 70%, which comprises mixing (a) an organic polyisocyanate with (b) one or more polymeric compounds having two or more isocyanate-reactive hydrogen atoms, (c) optionally crosslinking and/or chain-extending agents, (d) one or more carboxylic acids having a functionality of 2 or more, (e) a catalyst comprising a Lewis base component, and (f) optionally auxiliaries and additives to form a reaction mixture and reacting this reaction mixture to form the rigid polyurethane-polyamide foam. The present invention further relates to a thermoformable rigid polyurethane-polyamide foam obtained by such a process and also to the use of such a thermoformable rigid polyurethane-polyamide foam for interior lining or engine compartment lining of motor vehicles.

Abstract: Thermosetting resins and thermosetting composites comprising the thermosetting resins are hot-formable. The compositions result from contacting at least one thermosetting resin precursor with at least one hardener selected from acid anhydrides in the presence of at least one transesterification catalyst. The thermosetting resin precursor includes hydroxyl functions and/or epoxy groups, and optionally ester functions, and the total molar quantity of the transesterification catalyst is between 5 and 25% of the total molar quantity of hydroxyl and epoxy contained in the thermosetting resin precursor. Methods for manufacturing articles comprising the thermosetting resins and methods for recycling the thermosetting resins are also disclosed.

Abstract: Disclosed herein are compositions including a cross-linked polycarbonate. The cross-linked polycarbonate may be derived from a polycarbonate having about 0.5 mol % to about 5 mol % endcap groups derived from a monohydroxybenzophenone. A plaque including the composition can achieve a UL94 5VA rating. Also disclosed herein are articles including the compositions, methods of using the compositions, and processes for preparing the compositions.